Results

eNauka >  Results >  Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG ph
Title: Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG ph
Authors: Petzer, Andreas L; Fong, Dominic; Lion, Thomas; Dyagil, Irina; Masliak, Zvenyslava; Bogdanovic, Andrija D  ; Griskevicius, Laimonas; Lejniece, Sandra; Goranov, Stefan; Gercheva, Liana;
Stojanovic, Aleksandar; Peytchev, Dontcho; Tzvetkov, Nikolay; Griniute, Rasa; Oucheva, Radka; Grubinger, T; Kwakkelstein, Marthin; Rancati, Francesca; Gastl, Guenther A; Wolf, Dominik;
Issue Date: 2011
Publication: ONKOLOGIE
ISSN: 0378-584X Onkologie Search Idenfier
Type: Conference Paper
Collation: vol. 34 str. 264-264
WoS-ID: 000295160600709
URI: https://enauka.gov.rs/handle/123456789/821878
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
Mp. category will be shown later

Find the DOI

Google ScholarTM

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.